Navigation Links
Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
Date:6/8/2009

n focal dystonia was analyzed on the pooled data from 2 pivotal clinical trials in blepharospasm and cervical dystonia (343 NT 201 patients; 340 BTXCo* patients) and 1 post-stroke spasticity trial (73 NT 201 patients and 75 placebo patients). For the safety analyses, 6 clinical trials (blepharospasm, cervical dystonia, and upper limb spasticity) have been included (n=539 NT 201, n=442 BTXCo and n=75 placebo subjects). For the post-launch evaluation spontaneously reported adverse events were analyzed.

Results

In the randomized, active-controlled, double-blind studies in focal dystonia NT 201 and one other Botulinum toxin (BTXCo) have been used with a dose ratio of 1:1. The results demonstrate equivalent efficacy between the NT 201 and BTXCo. Onset, waning, and duration of effect were comparable. These findings have been confirmed by the Physician´s Global Impression of Efficacy: 70.6% of BTXCo patients and 71.8% of the NT 201 patients were rated as "good" or "very good." Additionally, in the placebo-controlled spasticity trial 62% of the caregivers rated the efficacy as good or very good compared to placebo (33%). 26.7% of patients in the NT 201 group, 26.0% in the BTXCo group, and 22.7% in the placebo group reported an adverse event. There were no clinically relevant differences between the two active treatment groups in the focal dystonia trials and between NT 201 and placebo in the post-stroke spasticity trial concerning safety aspects. All adverse reactions were either already known and/or were considered by the physician unlikely to be related to NT 201. More than 67,000 patients have been treated so far and no new safety concerns have been reported.

Second Study - Title

NT201 (Xeomin(R); botulinum neurotoxin free from complexing proteins) is efficacious and well-tolerated in upper limb spasticity of various etiologies authored by Barnes, M., Schnitzler, A., Amaral e Silva, A., Aquilar, M., Lehner
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
2. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
3. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
4. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting
10. TRACON Pharmaceuticals Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009
11. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
(Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... NEW YORK, Nov. 3, 2011 Intellect Neurosciences, ... the discovery and development of disease-modifying therapeutic agents ... diseases announced today that it has filed a ... its antibody methods application Serial  No. 10/084,380, one ...
... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... ended September 30, 2011, which reflect the Company,s continuing investment ... quarter with $202.7 million in cash and short-term investments, a ... quarter of 2011, the Company had a net loss of ...
Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 7
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... Carinsurancesavings.biz has released a new blog post ... insurance . , Purchasing an accidental death and dismemberment ... This type of rider provides benefits if the insured dies ... a lesser form of life insurance. , AD&D is ...
(Date:1/22/2015)... Recently, Weddingshe.com has added many trendy Champagne ... highest annual revenues in the past three years. Today, the ... dresses. , According to the sales manager of the company, ... them in 2015. This point can be reflected on the ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the ... in an effort to further promote visibility and adoption of ... long made AMA journals available via its subscription services, EBSCO ... Network. , Long known as both a subscription ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... reveals that there is no association between a restaurant worker,s ... able to provide a safe meal to a food allergic customer. ... as 8% of children in the UK alone. Allergic reactions can ... which can cause death. Led by Professor Helen Smith of Brighton ...
... care improves medical outcomes, investigators from the Regenstrief ... providing a call to action for the training ... well as the burgeoning scientific knowledge needed to ... the Patient-Centered Divide: Transforming Health Care Quality Through ...
... the National Institute of Standards and Technology (NIST) ... disease, an inherited degenerative brain disorder that usually ... leads to physical impairment, dementia and death. A ... has a 50-50 chance of getting the currently ...
... , This release is available in French ... of Granada research group composed of professors Antonio Campos ... and Juan de la Cruz Cardona (opticians) and the ophthalmologist ... the first bioartificial organ in Spain Researchers extracted pig ...
... release is available in French . Montreal, ... treat tics in Tourette syndrome may be as effective as ... a new study published in a special edition of the ... Research Centre of the Louis-H. Lafontaine Hospital affiliated with Universit ...
... Toronto General Hospital, University Health Network have shown in ... safely and effectively treat, re-assess and improve the function ... successfully transplanted into patients. The use of this technique ... outcomes after transplantation. In their pioneering work, a ...
Cached Medicine News:Health News:Training future doctors to enlist patients as partners in care 2Health News:New NIST SRM helps improve diagnosis of Huntington's disease 2Health News:Tourette Syndrome: non-drug therapy to reduce tics 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 2Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 3Health News:Toronto XVIV0 Lung Perfusion System allows high-risk lungs to be safely transplanted 4
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Intersurgical Incorporated manufactures high ... and moisture exchangers, ventilator ... hand-held nebulizers and an ... and connectors for anesthesia ...
... The Ulti-Mist™ HME product line has ... from pediatrics to adults and from intubated ... offer superior humidification for both anesthesia and ... and HME/Filters provide maximum protection for patients ...
Bacterial/Viral Filters for Anesthesia and Respiratory Applications...
Medicine Products: